BenQ Dialysis Technology, a subsidiary of Qisda, continues to expand its overseas market territory for its self-manufactured BenQ Qflux Dialyzer. Having successfully obtained licenses in Korea, China, and several countries in Southeast Asia (the Philippines, Thailand, Vietnam, and Myanmar) in recent years, BenQ officially attained a medical equipment license issued by the Ministry of Health in Indonesia in October 2021, becoming the only artificial dialyzer manufacturer in Taiwan to receive a license in Indonesia. This has set a new milestone for BenQ Dialysis Technology.

Indonesia is the fourth most populous country in the world. Its medical expenditure is the highest among the six ASEAN countries at USD29.1 billion in 2018. Despite these facts, 95% of the medical equipment market relies on imports, which total USD930 million, with an average annual compound growth rate of over 10%. This indicates that there is an increasing demand for medical products in Indonesia and market opportunities are huge. The incidence of treated end stage renal disease in 2018 was 236 PMP (per million people), equivalent to an annual increase of 64,000 people. Although 20% of patients are currently being treated, the potential for growth in the dialysis market is considerable with the government’s introduction of dialysis subsidies and the gradual economic growth.

Spark Huang, President of BenQ Dialysis Technology said: “In recent years, BenQ Dialysis Technology has been making proactive efforts to deepen its business in the field of dialysis. BenQ Dialysis Technology has teamed up with its investees including BenQ Biotech (Shanghai), K2 International Medical (including headquarters in Taiwan and branches in Shanghai and Thailand), Frismed (Indonesia), and E-Strong Medical Technology to provide one-stop products and services in Taiwan and overseas. Since its establishment seven years ago, BenQ Dialysis Technology has maintained annual sales growth of over 50% or even several times. With the license coupled with the effective channel deployment, overseas sales have also increased by more than 40% compared to last year.”

Spark Huang further stated: “BenQ Qflux Dialyzer has been licensed in Taiwan, Korea and several countries in Southeast Asia. With the new license for Indonesia, BenQ will do its utmost to expand its partner channels in the country, as well as other Southeast Asian markets to broaden its deployment and services overseas.”

BenQ Dialysis Technology possesses Qisda’s mature plastic model design, manufacturing, and plastic injection technologies. As well as this, the Company also has complete and extensive electronic manufacturing experience, and is one of the few AI dialysis plants in Taiwan that can independently integrate all upstream, midstream and downstream processes. The quality and effectiveness of the self-manufactured Hemodialyzer are on par with international leading brands. For example, the urea reduction ratio (URR) is better than the Taiwan Society of Nephrology standard by more than 10%, and the urea nitrogen dialysis adequacy (Kt/V) is better than the Taiwan Society of Nephrology standard by more than 20%.